We are live on ! Find out more
MBX

MBX Biosciences

118 hedge funds and large institutions have $836M invested in MBX Biosciences in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 29 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 9

99% more capital invested

Capital invested by funds: $420M → $836M (+$416M)

34% more funds holding

Funds holding: 88118 (+30)

32.04% more ownership

Funds ownership: 110.22%142.26% (+32%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 30

47% less call options, than puts

Call options by funds: $15.3M | Put options by funds: $29M

Holders
118
Holders Change
+30
Holders Change %
+34.09%
% of All Funds
1.55%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
39
Increased
29
Reduced
30
Closed
9
Calls
$15.3M
Puts
$29M
Net Calls
-$13.7M
Net Calls Change
-$12.9M
Name Holding Trade Value Shares
Change
Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$116M +$8.91M +666,666 +11%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$84.4M +$34.2M +2,556,708 +113%
O
3
OrbiMed
New York
$70.1M
NMC
4
NEA Management Company
Maryland
$63.3M
DTC
5
Deep Track Capital
Connecticut
$55.1M +$12.9M +961,408 +44%
NA
6
NVP Associates
California
$37.4M
EC
7
EcoR1 Capital
California
$37.2M +$13M +973,810 +85%
KCM
8
Kynam Capital Management
New Jersey
$35M +$26.7M +2,000,000 New
BlackRock
9
BlackRock
New York
$34.3M +$12.6M +945,915 +94%
Vanguard Group
10
Vanguard Group
Pennsylvania
$29.4M +$8.47M +633,678 +61%
DCM
11
Driehaus Capital Management
Illinois
$26.9M -$431K -32,267 -2%
Franklin Resources
12
Franklin Resources
California
$22.9M +$10.9M +812,436 +164%
CAM
13
Cormorant Asset Management
Massachusetts
$21.4M +$7.02M +525,000 +75%
WP
14
Woodline Partners
California
$21M +$4.01M +300,047 +33%
Citadel Advisors
15
Citadel Advisors
Florida
$17.4M +$13.3M +996,083 New
T. Rowe Price Associates
16
T. Rowe Price Associates
Maryland
$16.7M -$5.24M -392,184 -29%
PHP
17
Parkman Healthcare Partners
Connecticut
$13.5M -$1.32M -98,629 -11%
Millennium Management
18
Millennium Management
New York
$11.5M -$1.49M -111,424 -15%
TCM
19
TCG Crossover Management
California
$11.4M
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$11M -$4.63M -346,120 -36%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$8.3M +$1.68M +125,485 +36%
Goldman Sachs
22
Goldman Sachs
New York
$6.27M +$4.79M +358,121 New
State Street
23
State Street
Massachusetts
$5.59M +$724K +54,155 +20%
SSA
24
Schonfeld Strategic Advisors
New York
$4.95M -$4.66M -348,736 -55%
RSCM
25
Rock Springs Capital Management
Maryland
$4.95M +$3.78M +282,624 New

MBX Hedge Fund Activity: Q3 2025 in Review

118 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q3 2025, worth a combined $836M — up 99% from $420M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new MBX positions and 9 closed out — a net gain of 30 holders — while 29 added to existing stakes and 30 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $34.2M. The largest seller was MPM BioImpact, exiting entirely with an estimated $14.8M sold.

  • 118 institutional investors held MBX Biosciences (MBX) as of Q3 2025, up from 88 in Q2 2025.
  • Funds reported $836M of MBX Biosciences stock for Q3 2025, up 99% quarter-over-quarter.
  • 39 funds opened new MBX Biosciences positions in Q3 2025 and 9 closed out, a net change of +30 holders.
  • The largest MBX Biosciences buyer in Q3 2025 was Wellington Management Group, an estimated $34.2M added.
  • The largest MBX Biosciences seller in Q3 2025 was MPM BioImpact, an estimated $14.8M sold.

Based on aggregated 13F filings for Q3 2025.